Juva Life, Inc. (OTCQB: JUVAF) (CSE: JUVA) is engaged as a California-based company that is focused on the research, development, and commercialization of cannabis products. In addition to traditional cannabis products, Juva Life is working on cannabis-derived non-cannabinoid compounds for use in a medical setting. Shares of the California cannabis company are surging 30% through early trading on Thursday, October 14, 2021. Over the past thirty days, Juva Life has seen average daily volume of 228,795 shares. However, volume of 426,016 shares or dollar volume of $114,074, has already exchanged hands through early trading Thursday.
Shares of Juva Life are rallying after the company provided updates on its JUVA-19 class of compounds development. JUVA-19 is a cannabis-derived, non-cannabinoid small molecule that features broad spectrum anti-inflammation properties. Early pre-clinical results have shown the compound to inhibit IL1-beta and TNF-alpha. On October 6, 2021, the company filed a provisional patent with the U.S. Patent and Trademark Office regarding its JUVA-19 compounds.
Through pre-clinical in vivo validation studies, the company plans to leverage its expertise in chemistry and anti-inflammation treatments to develop natural and semi-synthetic non-cannabinoid compounds derived from the cannabis plant. Over time, management seeks to partner with “leading pharma and consumer companies seeking anti-inflammatory bioactives for their product pipelines.”
Juva Life CEO, Doug Chloupek states, “We are pleased of the progress of our internal research and development activities.” Mr. Chloupek continues, “Our next steps are to build upon our initial findings by profiling the Juva-019 class of compounds in gold standard in-vivo models of inflammation, paving the way for evidenced-based product development.”
Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.
